WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · HB 964

Legislative bill overview

HB 964 would establish regulatory frameworks for laboratory developed tests (LDTs) specifically during federally declared public health emergencies in Texas. The bill addresses how LDTs—diagnostic tests developed and validated by individual laboratories rather than commercial manufacturers—are overseen when emergency conditions require rapid testing deployment. This legislation would clarify state authority and requirements for these tests during crisis periods.

Why is this important

During public health emergencies like COVID-19, LDTs became critical tools for rapid diagnostic testing when commercial tests were unavailable or insufficient. However, the regulatory landscape for LDTs remains fragmented between federal FDA oversight and state laboratory licensing, creating gaps in accountability and quality assurance. Clear state-level guidance during emergencies could accelerate testing availability while protecting public health, or conversely, could create barriers to innovation depending on how regulations are structured.

Potential points of contention

  • Federal versus state regulatory authority: Tension exists between FDA jurisdiction over LDTs and state laboratory licensing boards; unclear how this bill delineates responsibilities or handles conflicts
  • Speed versus safety trade-offs: Emergency provisions that reduce validation requirements could expedite testing but may compromise quality assurance and accuracy safeguards
  • Laboratory burden and access: Regulatory requirements could either protect consumers or create compliance costs that disadvantage smaller, independent labs trying to serve underserved areas during emergencies

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.